Hypertension is a major cause of heart failure, evolving from left ventricular hypertrophy to systolic and diastolic dysfunction. Although effective heart failure therapy has been associated with a lowering or no change in systemic arterial blood pressure in long-term follow-up, this study describes the symptomatic, clinical, and left ventricular functional response of a subgroup of heart failure patients with a prior history of hypertension who demonstrated a paradoxical hypertensive response despite high-dose vasodilator therapy.
H eart failure continues to be a major and growing cause of cardiovascular morbidity and mortality. 1 Hypertension, a major risk factor for heart failure, causes left ventricular hypertrophy, impaired myocyte contractility, ventricular chamber remodeling, and eventually systolic and diastolic dysfunction. 2 After the development of symptomatic heart failure, the prognosis for survival has typically been considered bleak. 3 Vasodilator therapy in general, and angiotensin converting enzyme (ACE) inhibition therapy in particular have, however, dramatically improved survival by stabilizing the left ventricular remodeling process. 4 -6 Such therapy, based on the hemodynamic premise of lowering ventricular afterload and vascular impedance, has been associated with a significant first-dose hypotensive effect, as documented in numerous studies. [7] [8] [9] [10] In longer-term follow-up, a lesser but persistent reduction in blood pressure has been observed in most patients receiving vasodilator therapy. 7,8,10 -13 Adding ␤-receptor blockade to the therapeutic regimen has been repeatedly shown not only to stabilize but also to reverse the pernicious ventricular remodeling of heart failure, thereby improving myocardial energetics and systolic function. As a consequence, blood pressure is stabilized or slightly increased in response to chronic ␤-receptor blockade, consistent with an improvement in ventricular contractile function. 14, 15 Similarly, we have observed that systemic blood pressure stabilizes in patients functionally recovering from symptomatic heart failure while receiving chronic medical therapy. 16 Paradoxically some patients, most of whom had a prior history of hypertension, developed a sustained hypertensive response upon recovery from heart failure, despite high-dose vasodilator therapy. This study seeks to describe the symptomatic and clinical response and changes in left ventricular systolic function in heart failure patients demonstrating this paradoxical hypertensive response to vasodilator therapy, and to determine the incidence of this response in heart failure patients with a known history of hypertension.
MATERIALS AND METHODS

Study Patients
Patients with severe chronic heart failure, referred for either medical management or for possible cardiac transplantation, routinely underwent echocardiographic studies every 6 months and were prospectively entered into a database from August 1990 through January 1996. Patients were not entered if they were noncompliant with their medical regimen, had significant pulmonary, hepatic, and renal impairment, or if they suffered from any other chronic debilitating inflammatory, infectious, or neoplastic processes. Patients whose systolic blood pressure was Ն 140 mm Hg upon presentation were similarly excluded.
We considered only those patients who had a previous history of hypertension, and had at least two or more echocardiographic evaluations every 6 months. Forty-five patients were identified by these criteria.
This group of normotensive, previously hypertensive heart failure patients was subdivided into two groups: Group A (n ϭ 12), patients whose systolic blood pressure in the final follow-up was Ն 140 mm Hg; and Group B (n ϭ 33), patients who did not have a hypertensive response to therapy.
Medical Therapy For all referrals, vasodilator therapy was uptitrated either in the inpatient or outpatient setting using hemodynamic measurements and physical findings for guidance, as previously described. 16 Diuretic dosage was similarly adjusted according to need, as assessed by history and physical examination.
The dose of ACE inhibitor was increased progressively as long as systolic arterial pressure exceeded 90 mm Hg and end-organ perfusion was maintained. A total maximal dose of 80 mg per day of enalapril was administered twice daily. This dose was considered comparable to the 300 to 450 mg daily dose of captopril, which earlier studies had shown to be clinically and hemodynamically effective. 8, 13 Nitrates were initiated and the dosage increased for the following reasons: symptomatic ischemia; continued elevation of right ventricular filling pressures despite afterload reduction therapy; and for pulmonary hypertension in excess of 40 mm Hg or moderate to severe mitral regurgitation as determined by two-dimensional Doppler echocardiographic examination. The total maximal final dose of isosorbide dinitrate was 480 mg per day. Other vasodilators such as amlodipine were introduced only after maximal doses of ACE inhibitor.
␤-receptor blockade was initiated only after maximal titration of ACE-I/nitrate vasodilator therapy. ␤-1 receptor blockade was initiated with atenolol at 6.25 mg per day, with weekly increments of 6.25 mg, to a maximal dose of 50 mg twice daily, or until the resting heart rate decreased to 55 to 65 beats per minute. ␤-blockade was not used in patients with significant bronchospastic disease or unstable diabetic control.
Patient Follow-up Patients were contacted by telephone one to two times per week during initial dose titration and seen at biweekly to monthly intervals until clinical stabilization was achieved. Thereafter they were seen once every 3 months.
Two-dimensional Doppler echocardiograms were obtained at baseline and on a semiannual basis. Echocardiograms were read in a blinded fashion by staff echocardiographers not involved in the heart failure program. The severity of mitral regurgitation was graded as 1ϩ ϭ mild, 2ϩ ϭ mild/moderate, 3ϩ ϭ moderate, and 4ϩ ϭ severe.
All patients underwent dietary counseling to achieve weight control if indicated, and were counseled to pursue salt restriction and avoidance of any social alcohol use. All patients were urged to participate in a formal cardiac rehabilitation program initially, and thereafter to pursue an ongoing cycling or walking program 5 to 6 days per week.
Statistical Analysis All patients were followed for at least 6 months. Data are presented as mean Ϯ SD. Differences between group mean values were assessed with analysis of variance (Statview 4.1, Abacus Concepts, Inc., Berkeley, CA). For dichotomous data, 2 test was used. Statistical significance was defined as P Յ .05.
RESULTS
Patient Characteristics
Of the 12 patients who paradoxically developed hypertension during chronic therapy (Group A), seven were men, three were white; nine were black, and two of the 12 had ischemic cardiomyopathy. The patients, 60 Ϯ 10 years in age, had symptomatic heart failure for 6.3 Ϯ 4.3 years and their presenting New York Heart Association classification score averaged 2.9 Ϯ 0.7.
Six of the 12 patients had been referred for evaluation for cardiac transplantation. One patient had been dependent on intravenous inotropic support at the time of referral.
Baseline demographic, clinical, and echocardiographic characteristics of Group A closely matched those of the larger Group B (n ϭ 33) ( Table 1) .
Medications Ten of the 12 Group A patients were maintained on digoxin. In follow-up, 11 of 12 patients were receiving ACE inhibitors, 10 patients were taking isosorbide dinitrate, diuretics (n ϭ 10), atenolol (n ϭ 7), amlodipine (n ϭ 4), amiodarone (n ϭ 1), losartan (n ϭ 1), and hydralazine (n ϭ 1). Initial and final medication dosages for Group A are shown in Table 2 , and were comparable to those of Group B.
Clinical Status During the 2.0 Ϯ 0.5 years of followup, for the 12 Group A patients, intravenous inotropic support was no longer required by any patient, none were transplanted, and no patient died.
The group experienced symptomatic relief, with an improvement in New York Heart Association classification from 2.9 Ϯ 0.8 to 1.3 Ϯ 0.5 at final follow-up (P Յ .0001). Hospitalizations decreased similarly, from 3.7 Ϯ 3.5 to 0.3 Ϯ 0.5 per year (P ϭ .006). 
Heart Rate and Blood Pressure Response to Therapy
By definition, all patients in Groups A and B had the diagnosis of hypertension before the development of clinical heart failure. For Group A, heart rate declined from 90 Ϯ 16 to 74 Ϯ 14 beats per minute (P ϭ .004).
Although during the first 3 months of follow-up there was no significant change in systolic blood pressure (116 Ϯ 14 to 126 Ϯ 21 mm Hg; P ϭ NS), it increased to 154 Ϯ 13 mm Hg at final follow-up (P Ͻ .0001) 2.0 Ϯ 0.5 years later (Table 5) . Similarly, diastolic blood pressure remained unchanged during the first 3 months (71 Ϯ 9 to 80 Ϯ 10 mm Hg; P ϭ NS), but rose to 85 Ϯ 14 mm Hg at the conclusion of the study (P ϭ .004). Pulse pressure changed correspondingly, from 45 Ϯ 13 to 69 Ϯ 17 mm Hg (P ϭ .002). Although Group B was clinically comparable to Group A (Table 1) and demonstrated similar symptomatic improvement, final systolic blood pressure was unchanged for Group B (Table 4) , at 114 Ϯ 13 mm Hg, versus 154 Ϯ 13 mm Hg for Group A. Diastolic blood pressure dropped (79 Ϯ 6 to 73 Ϯ 9 mm Hg; P ϭ .01), with a corresponding small rise in pulse pressure (35 Ϯ 10 to 40 Ϯ 10 mm Hg; P ϭ .02). Renal function, as estimated by blood urea nitrogen, remained stable (22 Ϯ 7 to 19 Ϯ 9 mg/dL; P ϭ NS), similar for both groups. In Group A, ␤-receptor blocker therapy (n ϭ 7) had no impact on the final systolic blood pressure reading, being 159 Ϯ 15 mm Hg in the group receiving vasodilators without ␤-blockers and 150 Ϯ 11 mm Hg in those receiving the ␤-adrenergic receptor blockers (P ϭ NS). In contrast to Group B, Group A had a preponderance of female and black patients (Table 1) .
Thus, 12 of the 45, or 27%, of patients with heart failure and an antecedent history of hypertension demonstrated a paradoxical hypertensive response to therapy.
DISCUSSION
We have identified a group of normotensive patients with severe heart failure whose left ventricular function and symptoms were greatly improved by uptitrated high-dose vasodilator therapy, but who, paradoxically, developed hypertension. All 12 patients had a previous history of high blood pressure, which reappeared only after their cardiac function improved.
Clinical Response Although this group of patients presented with severe symptomatic heart failure, relatively tachycardic, and with significant derangement of left ventricular systolic function, the systolic arterial blood pressure on initial presentation reflects a rela- tively "compensated" group, with the potential to respond to progressive intensive heart failure therapy. This is borne out by the group's ability to tolerate high doses of vasodilators, and by their dramatic clinical improvement in follow-up.
Left Ventricular Function Symptomatic recovery in
Group A was matched by a progressive increase in their left ventricular ejection fraction, a concomitant decrease in left ventricular end-diastolic size, and in the severity of their mitral regurgitation. Contributing mechanisms to this improvement in left ventricular systolic function are likely to be multifactorial and may vary at different stages of therapy and for different dosages of medications. Vasodilator therapy is classically associated with a first-dose hypotensive effect. [7] [8] [9] [10] This was not observed in our patient population because all patients were already receiving ACE inhibitors at the time of referral. The early effect of vasodilator therapy would beneficially alter pre-and afterloading conditions of the impaired ventricles. 8, 13, 17 The resultant reduction in the severity of mitral regurgitation would enhance the contribution of forward cardiac output to the generation of systolic blood pressure. 18, 19 Thus, longer-term studies have shown stabilization of blood pressure with continued vasodilator therapy. 7,8,10 -13 Correspondingly, our 1-to 3-month interim blood pressure measurement showed no significant change in systolic and diastolic blood pressures.
In this study, the paradoxical hypertensive response developed later, at a time when vasodilator therapy had been maximized and additional therapy was being introduced. Although systolic and mean arterial blood pressures are not adequate measures of left ventricular afterload, in the face of an actual rise in pressure in long-term follow-up, the increase in left ventricular ejection fraction with smaller end-diastolic size would suggest that improved contractility is contributing to the observed recovery. Such enhanced contractile potential has been observed with high-dose ACE inhibitor-nitrate and with ␤-blocker therapy. 14 -16 In longer-term follow-up, mechanisms other than loading effects may be playing a role. Angiotensin converting enzyme inhibitors may lower myocardial oxygen demand. 20 The associated regression in compensatory hypertrophy and collagen deposition in the extracellular and perivascular myocardial matrix may enhance oxygen delivery to ventricular myocytes. 21 Blocking angiotensin II production has also been associated with an increase in the density of myocardial ␤-adrenergic receptors, 22, 23 as well as with an actual increase in myocyte contractility, 24 thus potentially improving myocardial energetics and contractile function.
Hypertensive Response Enhanced ventricular efficiency results in greater systolic emptying, a higher forward stroke volume, cardiac output, and a greater systolic pressure. The greater recovery of left ventricular systolic function in Group A may in part account for the higher arterial pressures observed. In contrast, in Group B, with lesser improvement in systolic function, a smaller increase in forward stroke volume may have conceivably mitigated the effect on systemic arterial pressure. A paradoxical hypertensive response despite high vasodilator doses occurred in less than one-third of patients with an antecedent history of hypertension, more commonly in women and in blacks. Measured blood pressure reflects the net effect of vasodilator therapy in heart failure: a lowering of peripheral vascular tone that decreases arterial pressure is offset by an increase in forward stroke volume, which raises pressure. Presumably, the failure of arterial compliance to rise and of peripheral vascular resistance to decrease, thereby not accommodating the increased cardiac output and stroke volume, accounted for the increase in arterial blood pressure in Group A.
The average age of Group A was 60 Ϯ 10 years. Age-related impaired arterial compliance may have contributed to the elevated systolic blood pressure. Additionally, escape pathways to ACE inhibition may raise tissue angiotensin-II production, 25 and secondarily endothelin-1, 26 both potent vasoconstrictors that enhance vasomotor tone and elevate blood pressure. Angiotensin-II may stimulate aldosterone production to alter renal sodium handling and maintain chronic blood pressure elevation. 26, 27 Furthermore, some patients with hypertension may have increased responsiveness to pressor hormones, including angiotensin.
28
Implications Improved ventricular performance in response to vasodilator therapy in some patients with a history of hypertension may lead to a restitution of the baseline hypertensive pathophysiology. If unchecked, this would establish a vicious cycle where the recurrent hypertension would result in new episodes of heart failure, each less amenable to correction as treatment strategies are exhausted. It is incumbent upon the physician to identify such patients and aggressively treat them while in the recovery phase with more intensive neurohormonal blockade, adding ␤-blockers, angiotensin II receptor antagonists, and spironolactone. Such promising experimental therapies as T-channel calcium blockers, 29 endopeptidase inhibitors, and endothelin antagonists 30 may also prove beneficial.
Conclusion
We have reported on a group of patients who respond to intensive vasodilator therapy for heart failure with significant symptomatic recovery and improvement in left ventricular systolic function. Although vasodilator heart failure therapy would classically be expected to achieve these results with a lowering of systolic blood pressure, this subset of patients (27% of those having a history of hypertension) developed a paradoxical hypertensive response to vasodilator therapy and as such would benefit from efforts at more comprehensive blockade of the neurohormonal axis.
